Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability Study of WD-1603 Carbidopa/Levodopa ER Tablets in Healthy Subjects
NCT05128175Phase 1Completed
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of carbidopa + levodopa in Parkinson's disease (PD) (5 arms), sponsored by Shanghai WD Pharmaceutical Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration at 24 hours and Duration for Levodopa Concentrations >= 50% of Cmax at 24 hours. Started Oct 2021; status: completed.
02
Drugs
carbidopa + levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05128175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05128175.